The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cabozantinib (C) versus placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy: Outcomes in prespecified subgroups based on prior VEGFR-targeted therapy.
 
Jorge Hernando
Speakers' Bureau - Advanced Accelerator Applications; Angelini Pharma; Bayer; Eisai; Ipsen; Novartis; Roche
Travel, Accommodations, Expenses - Advanced Accelerator Applications; Eisai; Ipsen; Novartis; Roche
 
Jaume Capdevila
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Esteve; Exelixis; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Sanofi
Speakers' Bureau - Bayer; Eisai; Esteve; Hutchison MediPharma; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Ipsen (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Eisai; Ipsen; Pfizer
 
Bruce Robinson
Leadership - Cochlear; Mayne Pharma
Stock and Other Ownership Interests - Cochlear; Mayne Pharma
Consulting or Advisory Role - Eisai; Loxo
Speakers' Bureau - Eisai
Travel, Accommodations, Expenses - Eisai
 
Steven I. Sherman
Employment - Southwest OB/GYN Associates (I)
Honoraria - Eisai; Exelixis
Consulting or Advisory Role - Exelixis; Lilly; Loxo
Research Funding - Exelixis (Inst)
 
Barbara Jarząb
Honoraria - Bayer; Eisai; Exelixis; Ipsen; Lilly; Sanofi
Consulting or Advisory Role - AstraZeneca; Ewopharma; SOBI
Travel, Accommodations, Expenses - Ipsen; Novartis; Sanofi
 
Chia-Chi Lin
Honoraria - Daiichi Sankyo; Lilly; Novartis; Novartis; Roche
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Novartis; PharmaEngine
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Daiichi Sankyo; Lilly; Novartis
 
Fernanda Vaisman
Consulting or Advisory Role - AstraZeneca/Merck; Bayer Health; Ipsen; Lilly
Speakers' Bureau - AstraZeneca/Merck; Bayer; Sanofi; United Medical
 
Ana Hoff
Honoraria - Bayer
Research Funding - Bayer; Eisai; Exelixis; Lilly; Lilly
 
Erika Hitre
No Relationships to Disclose
 
Daniel W. Bowles
Consulting or Advisory Role - Blueprint Medicines; Exelixis
 
Suvajit Sen
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Jennifer Wright Oliver
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Bhumsuk Keam
Honoraria - AstraZeneca; Merck; MSD Oncology
Consulting or Advisory Role - ABL Bio; CBS Bioscience; Cellid; Handok; NeoImmuneTech; Trial Informatics
Research Funding - AstraZeneca; MSD Oncology; Ono Pharmaceutical
 
Marcia S. Brose
Honoraria - Bayer; Eisai; Lilly
Consulting or Advisory Role - Bayer; Blueprint Medicines; Eisai; Exelixis; Lilly; Loxo
Research Funding - Bayer (Inst); Blueprint Medicines (Inst); Eisai (Inst); Exelixis (Inst); Lilly (Inst); Loxo (Inst)